October 3, 2018
Kaken Pharmaceutical said on October 2 that the company and Main Life Corp. have entered into an exclusive distribution agreement for Kaken’s topical onychomycosis treatment efinaconazole in Hong Kong and Macau. Under the deal, the Hong Kong firm aims to...read more